Letter to the Editor regarding Response to “Letter to Editor: “Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19”

• Takahiro Takazono,
• Satoki Fujita,
• Takuji Komeda,
• Shogo Miyazawa,
• Yuki Yoshida,
• Yoshitake Kitanishi,
• Masahiro Kinoshita,
• Satoshi Kojima,
• Huilian Shen,
• Takeki Uehara,
• Naoki Hosogaya,
• Naoki Iwanaga,
• Hiroshi Mukae

Affiliations

Takahiro Takazono

Department of Respiratory Medicine, Nagasaki University Hospital

Satoki Fujita

Data Science Department, Shionogi & Co., Ltd.

Takuji Komeda

Data Science Department, Shionogi & Co., Ltd.

Shogo Miyazawa

Data Science Department, Shionogi & Co., Ltd.

Yuki Yoshida

Data Science Department, Shionogi & Co., Ltd.

Yoshitake Kitanishi

Data Science Department, Shionogi & Co., Ltd.

Masahiro Kinoshita

Medical Affairs Department, Shionogi & Co., Ltd.

Satoshi Kojima

Medical Affairs Department, Shionogi & Co., Ltd.

Huilian Shen

Medical Affairs Department, Shionogi & Co., Ltd.

Takeki Uehara

Drug Development and Regulatory Science Division, Shionogi & Co., Ltd.

Naoki Hosogaya

Department of Respiratory Medicine, Nagasaki University Hospital

Naoki Iwanaga

Department of Respiratory Medicine, Nagasaki University Hospital

Hiroshi Mukae

Department of Respiratory Medicine, Nagasaki University Hospital